Pathstone Holdings
ADMA icon

Pathstone Holdings’s ADMA Biologics ADMA Stock Holding History

Pathstone Holdings’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,545
Closed -$229K – 2225
2025
Q4 		$229K Sell
12,545
-1,825
-13% -$30.8K ﹤0.01% 2062
2025
Q3 		$211K Buy
14,370
+1,142
+9% +$19.6K ﹤0.01% 2184
2025
Q2 		$241K Buy
+13,228
New +$270K ﹤0.01% 2001

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Pathstone Holdings's ADMA Position: Q1 2026 in Review

Pathstone Holdings sold out of ADMA Biologics (ADMA) in Q1 2026, closing a stake of 12,545 shares — an estimated $229K sold.

Pathstone Holdings first reported a position in ADMA in Q2 2025 and held it in 3 quarters. The position peaked at $241K in Q2 2025. 357 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Pathstone Holdings reported no remaining ADMA Biologics position as of Q1 2026 after selling out during the quarter.
  • Pathstone Holdings sold 12,545 ADMA Biologics shares in Q1 2026, an estimated $229K.
  • Pathstone Holdings first reported a position in ADMA Biologics in Q2 2025 and held it in 3 quarters.
  • Pathstone Holdings's ADMA Biologics position peaked at $241K in Q2 2025.
  • 357 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Pathstone Holdings's 13F filing for Q1 2026, filed 11 May 2026.